Opioid related disorder - Pipeline Insight, 2024

This “Opioid related disorder - Pipeline Insight, 2024,” report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Opioid related disorder pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Opioid related disorder Understanding

Opioid related disorder: Overview

Opioids are a class of drugs that bind with the opioid receptor present on the central nervous system in the brain and body to reduce the sensation of pain. Opioids predominantly include prescription pain relievers, synthetic opioids, and heroines. Although opioids reduce the perception of pain but chronic use of opioids can cause distress and impairment. Opioid related disorder includes overpowering desire to use opioids, dependence, increased opioid tolerance, and addictions which represents the most severe form of the disorders. When discontinued, the individual suffers from withdrawal syndrome.

Symptoms
Symptoms can include nausea, vomiting, weakened immune system, clogged blood vessels, hallucinations. Addicted people when discontinue opioids consumption often suffer from withdrawal symptoms which predominantly include anxiety, insomnia, agitations, muscle ache, tremors, and extreme mental and physical discomfort.

Diagnosis
Opioid related disorder is diagnosed by clinicians by taking history, evaluating symptoms, using clinical information to identify a problematic pattern of opioid related impairment and distress as well as using 11 diagnostic criteria mentioned in Diagnostic and Statistical Manual of Mental Disorders, fifth edition.

Treatment
An effective treatment for opioid related disorder generally includes pharmacotherapy. Three FDA approved medications present for the treatment of individuals with opioid related disorder are naltrexone, methadone, and buprenorphine. These medications are more successful than other treatments for improving retention in addiction treatment.

Opioid related disorder Emerging Drugs Chapters

This segment of the Opioid related disorder report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Opioid related disorder Emerging Drugs

ASP8062: Astellas PharmaAstellas Pharma’s lead drug candidate, ASP8062, is an analgesic class drug. It is an orally active ?-amino-butyric acid type B (GABAB) receptor positive allosteric modulator currently in phase II development. Phase 2 data demonstrated that ASP8062 for the treatment of Opioid related disorder as well as pain has beneficial effects. It was safe and well tolerated by the healthy subjects. It enhances the GABAergic transmission mediated by GABAB receptors by increasing the potency of endogenous agonist without overstimulating the receptor.

OPNT-003 (Intranasal Nalmefene): Opiant PharmaceuticalsOpiant Pharmaceuticals “breakthrough” drug OPNT-003 is a long lasting opioid antagonist for the treatment of Opioid overdose and has demonstrated positive data from its phase I trials.

Opioid related disorder: Therapeutic Assessment

This segment of the report provides insights about the different Opioid related disorder drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Opioid related disorder

There are approx. 10+ key companies which are developing the therapies for Opioid related disorder. The companies which have their Opioid related disorder drug candidates in the mid to advanced stage, i.e. phase III and Phase II include, Astellas Pharma and others.

Phases

This report covers around 10+ products under different phases of clinical development like

• Late -stage products (Phase III and Phase II/III)
• Mid-stage products (Phase II and Phase I/II)
• Early-stage products (Phase I/II and Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Route of Administration

Opioid related disorder pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Subcutaneous
• Intravenous
• Oral
• Intramuscular

Molecule Type

Products have been categorized under various Molecule types such as

• Small molecules
• Natural metabolites
• Monoclonal antibodies

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Opioid related disorder: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Opioid related disorder therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Opioid related disorder drugs.

Report Highlights

• The companies and academics are working to assess challenges and seek opportunities that could influence Opioid related disorder R&D. The therapies under development are focused on novel approaches to treat/improve Opioid related disorder.

Opioid related disorder Report Insights

• Opioid related disorder Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Opioid related disorder Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Opioid related disorder drugs?
• How many Opioid related disorder drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Opioid related disorder?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Opioid related disorder therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Opioid related disorder and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• GW Pharmaceuticals
• Opiant Pharmaceuticals
• Trevi Therapeutics
• Aphios
• Astellas Pharma

Key Products

• ASP8062
• OPNT-003
• Cannabidiol
• Nalbuphine
• APH-1501

This product will be delivered within 2 business days.